Tovaxin Autologous T cell vaccine

BIOLOGICAL2 trials

Sponsors

Opexa Therapeutics, Inc.

Conditions

Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary ProgressiveRelapsing-Remitting Multiple Sclerosis

Phase 1

Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis

CompletedNCT00587691

Opexa Therapeutics, Inc.Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive

Start: 2002-07-31End: 2008-12-31Updated: 2017-01-11

Phase 2

Autologous T Cell Vaccine (TCV) for Multiple Sclerosis

CompletedNCT00245622

Opexa Therapeutics, Inc.Relapsing-Remitting Multiple Sclerosis

Start: 2006-05-31End: 2008-09-30Updated: 2014-03-10